- 抑制劑
- 研究領(lǐng)域
- PI3K/Akt/mTOR信號(hào)通路
- 表觀(guān)遺傳
- 甲基化
- 免疫&炎癥
- 酪氨酸蛋白激酶
- 血管生成
- 凋亡
- 自噬
- 內(nèi)質(zhì)網(wǎng)應(yīng)激&UPR響應(yīng)
- JAK/STAT信號(hào)通路
- MAPK信號(hào)通路
- 細(xì)胞骨架
- 細(xì)胞周期
- TGF-beta/Smad信號(hào)通路
- 化合物庫(kù)
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細(xì)胞核與細(xì)胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲(chǔ)液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 動(dòng)物實(shí)驗(yàn)
- 鼠尾直接PCR試劑盒(快速基因型鑒定)
- 小鼠CD3+ T細(xì)胞分選試劑盒
- 小鼠CD4+ T細(xì)胞分選試劑盒
- 小鼠CD8+ T細(xì)胞分選試劑盒
- 新產(chǎn)品
- 聯(lián)系我們
2010年1月至今，引用Selleck產(chǎn)品的頂級(jí)學(xué)術(shù)期刊文獻(xiàn)已達(dá)篇！
已有十六位諾貝爾獎(jiǎng)得主使用Selleck產(chǎn)品發(fā)表文獻(xiàn)52篇！
David Baker
2024年獲得諾貝爾化學(xué)獎(jiǎng)
Michael Houghton
2020年獲得諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)
Charles M. Rice
2020年獲得諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)
- Nat Commun, 2020, 11(1):1677
- bioRxiv, 2020, 2020.10.09.334128
- bioRxiv, 2020, 2020.01.20.910927
- Viruses, 2019, 11(11)E1039
- Cell Rep, 2018, 25(4):833-840.e3
- Cell, 2018, 172(3):423-438.e25
- Gastroenterology, 2017, 153(2):566-578.e5
- Gastroenterology, 2016, 150(1):82-85.e4
- Antimicrob, 2016, 60(6):3786-93
- Nature, 2015, 524(7566):471-5
- Antimicrob, 2015, 59(6):3482-92
- J Virol, 2014, 88(20):12098-111
- Antimicrob, 2014, 58(9):5386-94
- J Virol, 2013, 87(13):7593-607
- Nature, 2013, 501(7466):237-41
- Nature, 2013, 99(1):6-11
- Antimicrob, 2012, 56(10):5365-73
William G. Kaelin Jr
2019年獲得諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)
Peter J. Ratcliffe
2019年獲得諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)
Gregg L. Semenza
2019年獲得諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)
Shinya Yamanaka
2012年獲得諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)
Aziz Sancar
2015年獲得諾貝爾化學(xué)獎(jiǎng)
化合物庫(kù)
提供840種人類(lèi)內(nèi)源代謝物小分子集合，涉及多個(gè)代謝通路，可用于高通量篩選和高內(nèi)涵篩選，為人類(lèi)開(kāi)辟腫瘤等多種疾病治療的新途徑。
新產(chǎn)品
G150 is a potent and highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with IC50 of 10.2 nM.
TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.
KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models.
Mizagliflozin is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.
Guadecitabine (SGI-110) is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine.
CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8?nM, 382 nM, 85 nM, 1200 nM, 2?nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.
INT-777 (S-EMCA) is a novel potent and selective TGR5 agonist with EC50 values of 0.18 μM, 3.9 μM and 1.45 μM for WT TGR5, TGR5(N76A) and TGR5(Y89F) respectively.
BAY 1125976 is a selective allosteric AKT1/2 inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity of AKT1 (IC50?=?5.2 nM at 10 μM ATP and 44 nM at 2 mM ATP) and AKT2 (IC50?=?18 nM at 10 μM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive on AKT3 (IC50?=?427 nM at 10 μM ATP).
Copyright 2013 Selleck中國(guó). All Rights Reserved.
滬ICP備13045345號(hào)-1滬公網(wǎng)安備 31011502012800號(hào)
